ASND1N Stock Chart & Stats
$4270.00
$0.00(0.00%)
At close: 4:00 PM EDT
$4270.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3,460.21 - $4,615.10
Previous CloseN/A
Volume0.00
Average Volume (3M)12.00
Market Cap
$259.99B
Enterprise Value$17.81K
Total Cash (Recent Filing)$811.92M
Total Debt (Recent Filing)$449.89M
Price to Earnings (P/E)16.7
Beta0.02
Next Earnings
Nov 11, 2026EPS Estimate
16.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)12.10
Shares Outstanding62,376,846
10 Day Avg. Volume0
30 Day Avg. Volume12
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)-67.58
Price to Sales (P/S)15.90
P/FCF Ratio252.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5,739.84Price Target Upside34.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)252.87
Revenue Forecast (FY)$24.52B
Bulls Say, Bears Say
Bulls Say
Commercial Growth And Portfolio ScaleRapid product growth demonstrates that Ascendis is converting its endocrinology portfolio into meaningful commercial revenue. YORVIPATH provides a substantial growth engine, while SKYTROFA and YUVIWEL add diversification, improving the prospects for a broader and more durable revenue base.
Strong Cash Generation And Low LeverageA large cash balance, absence of bank and convertible debt, and strong operating cash flow guidance give Ascendis flexibility to fund launches, research, and business development internally. This reduces financing pressure and supports continued investment across its commercial and pipeline programs.
TransCon Pipeline And Strategic ControlRegaining full rights expands Ascendis’s strategic control over a potentially broad metabolic and cardiovascular pipeline. The TransCon platform can support multiple long-acting therapies, giving the company more options to develop assets independently, seek partners, and extend growth beyond current endocrine products.
Bears Say
Unproven Earnings DurabilityThe recent profitability inflection is not yet proven across a full operating history. Losses and negative margins in prior years indicate that earnings may remain sensitive to launch execution, development spending, and product mix, making the current run-rate less dependable than a long-established profit record.
Reported Profit Aided By One-time IncomeThe priority review voucher sale materially inflated reported operating profit and net income, creating a gap between accounting results and underlying recurring profitability. Future earnings comparisons will face a difficult base, while adjusted results better reflect the continuing cost and revenue balance.
YUVIWEL Royalty BurdenThe settlement removes litigation uncertainty but imposes a significant royalty burden on YUVIWEL sales through May 2030. These payments will reduce the product’s contribution margin and could limit how much of its commercial growth converts into operating profit, particularly during the launch investment period.
Ascendis Pharma News
ASND1N FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $3460.21 and its highest was $4615.10 in the past 12 months.
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is $259.99B.
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is Nov 11, 2026 which is in 40 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Aug 13, 2026. The company reported $58.203 earnings per share for the quarter, beating the consensus estimate of $30.788 by $27.415.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is 16.56.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 62,376,846 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of $58.203 in its last earnings report, beating expectations of $30.788. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Currently, no hedge funds are holding shares in MX:ASND1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5,739.84 (34.42% Upside)
$5,739.84 (34.42% Upside)
Blogger Sentiment
Bullish
MX:ASND1N Sentiment 60%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $6.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
104.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
ASND1N Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and clear early successes: double-digit top-line expansion with EUR 315 million in product revenue, blockbuster-level performance from YORVIPATH (EUR 252 million), a successful SKYTROFA base (>20,000 patients), and a promising early U.S. launch for YUVIWEL with rapid enrollments and reimbursement approvals. Robust clinical readouts (COACH arm-span gains) and progressing partnerships reinforce long-term upside. Offsetting these positives were elevated R&D and SG&A spending, reliance on a one-time PRV sale to bolster reported profit (non-IFRS net profit materially lower at EUR 61 million), and legal/regulatory uncertainties (U.S. IP dispute and confirmatory trial dependence). Overall, highlights outweigh the lowlights given accelerating commercial traction, a strong cash position and no debt, but investors should monitor expense trajectory and the legal/regulatory developments.View all MX:ASND1N earnings summariesASND1N Stock 12 Month Forecast
Average Price Target
$5,739.84
▲(34.42% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Ultragenyx Pharmaceutical
―
Xeris Pharmaceuticals
―
―
MBX Biosciences, Inc.
―